“I am pleased to report that we have reached a new pivotal point for our proprietary ExoPTEN drug, primarily in advancing our United States Food and Drug Administration regulatory strategy and the commercialization of our exosome-based technology portfolio,” said Dr. Lior Shaltiel, CEO of NurExone.